Amneal Pharmaceuticals (AMRX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Amneal Pharmaceuticals (AMRX)
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Key Insights
Critical company metrics and information
Share Price
$8.09Market Cap
$2.51 BillionTotal Outstanding Shares
309.84 Million SharesTotal Employees
7,700Dividend
No dividendIPO Date
May 7, 2018SIC Description
Pharmaceutical PreparationsHomepage
https://www.amneal.com
Historical Stock Splits
If you bought 1 share of AMRX before August 26, 2013, you'd have 0.04 shares today.
Execution Date | Split Amount |
---|---|
August 26, 2013 | 1-for-25 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $-78.63 Million |
Net Cash Flow From Operating Activities | $312.84 Million |
Net Cash Flow From Operating Activities, Continuing | $312.84 Million |
Exchange Gains/Losses | $-58,000.00 |
Net Cash Flow From Financing Activities, Continuing | $-251.42 Million |
Net Cash Flow From Financing Activities | $-251.42 Million |
Net Cash Flow, Continuing | $-17.20 Million |
Net Cash Flow | $-17.26 Million |
Net Cash Flow From Investing Activities, Continuing | $-78.63 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Research and Development | $182.53 Million |
Net Income/Loss Attributable To Parent | $-179.73 Million |
Costs And Expenses | $2.80 Billion |
Basic Earnings Per Share | $-0.86 |
Operating Income/Loss | $187.73 Million |
Income Tax Expense/Benefit | $23.32 Million |
Preferred Stock Dividends And Other Adjustments | $4.73 Million |
Income/Loss From Continuing Operations Before Tax | $-123.16 Million |
Cost Of Revenue | $1.73 Billion |
Selling, General, and Administrative Expenses | $456.75 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $37.98 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $4.73 Million |
Operating Expenses | $759.67 Million |
Diluted Earnings Per Share | $-0.85 |
Gross Profit | $947.39 Million |
Income/Loss From Continuing Operations After Tax | $-146.48 Million |
Revenues | $2.68 Billion |
Diluted Average Shares | $328.54 Million |
Nonoperating Income/Loss | $-310.88 Million |
Other Operating Expenses | $120.38 Million |
Benefits Costs and Expenses | $2.80 Billion |
Basic Average Shares | $331.46 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-184.45 Million |
Net Income/Loss | $-146.48 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities And Equity | $3.46 Billion |
Liabilities | $3.49 Billion |
Accounts Payable | $235.00 Million |
Noncurrent Assets | $1.95 Billion |
Temporary Equity | $59.89 Million |
Equity Attributable To Parent | $-93.43 Million |
Equity | $-93.57 Million |
Current Assets | $1.51 Billion |
Other Non-current Assets | $736.48 Million |
Wages | $64.90 Million |
Fixed Assets | $431.02 Million |
Inventory | $596.36 Million |
Noncurrent Liabilities | $2.40 Billion |
Long-term Debt | $2.39 Billion |
Current Liabilities | $1.10 Billion |
Other Non-current Liabilities | $5.15 Million |
Other Current Assets | $916.93 Million |
Equity Attributable To Noncontrolling Interest | $-135,000.00 |
Other Current Liabilities | $795.31 Million |
Intangible Assets | $780.19 Million |
Assets | $3.46 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.